Trial Profile
A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumours
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs TAK 243 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 09 Nov 2016 Status changed from recruiting to completed.
- 16 Feb 2014 New trial record